應(yīng)用指南 - 利用NK-Xpander進行NK細胞擴增與鑒定 Expansion and characterization of human natural killer (NK) cells_第1頁
應(yīng)用指南 - 利用NK-Xpander進行NK細胞擴增與鑒定 Expansion and characterization of human natural killer (NK) cells_第2頁
應(yīng)用指南 - 利用NK-Xpander進行NK細胞擴增與鑒定 Expansion and characterization of human natural killer (NK) cells_第3頁
應(yīng)用指南 - 利用NK-Xpander進行NK細胞擴增與鑒定 Expansion and characterization of human natural killer (NK) cells_第4頁
應(yīng)用指南 - 利用NK-Xpander進行NK細胞擴增與鑒定 Expansion and characterization of human natural killer (NK) cells_第5頁
已閱讀5頁,還剩4頁未讀, 繼續(xù)免費閱讀

下載本文檔

版權(quán)說明:本文檔由用戶提供并上傳,收益歸屬內(nèi)容提供方,若內(nèi)容存在侵權(quán),請進行舉報或認領(lǐng)

文檔簡介

APPLICATIONNOTECTSNK-XpanderMedium

Expansionandcharacterizationofhumannaturalkiller(NK)cells

OptimizeyourNKcellexpansionprotocolwithCTSNK-XpanderMedium

Introduction

Naturalkiller(NK)cellsarelymphocytesthateitherdirectlyattackoractivatetheadaptiveimmunesysteminresponsetodetectionofmalignantorvirallyinfectedcells.They

haveawell-knownsafetyprofileandtheabilitytoactasallogeneicimmunemodulators,whichmakesNKcellsanattractiveoptionforoff-the-shelfimmunotherapeutics[1].

Intheclinicalsetting,strategiesarebeingdevelopedtoimproveNKcellfunction,persistence,andtraffickingtotumorsites[2].Theseincludeinsertingchimericantigenreceptors(CARs)andusingcomplementaryantibodiestoenhancetheidentificationanddestructionoftumorcells,aswellasexvivoexpansionandactivationtechniques.

ExpandAnalyze

?CTSNK-XpanderMedium

?RecombinanthumanIL-2

?HumanABserum

?Countess3FLAutomatedCellCounter

?AttuneNxTAcousticFocusingCytometer

?Stainingsolutionsandmonoclonalantibodies

Figure1.Optimizedworkflowforfeeder-freeexpansionandcharacterizationofNKcells.

Liuetal.[2]outlinethemanyexpansionandactivation

strategiesunderexploration,includingcytokine-only

expansion,autologousandallogeneicfeederstrategies,

engineeredcelllinefeeder–basedsystems,andeven

strategiestoengineercell-freeparticlesthatmimicthe

activityofengineeredfeedercells.Feeder-basedprotocolshavehistoricallyprovidedthehighestratesofexpansion.Thetypicalexpansionrangeislessthan10-foldfor

cytokine-onlysystems,lessthan500-foldforautologous

andallogeneicfeeder–basedsystems,andwellover1,000-foldforengineeredcelllinefeeder–basedsystems[2].

Safetyconcernsaboutfeedercells,includingtheriskof

contaminatingcellsinthefinaltherapeuticproduct,makefeeder-freesystemsadesirablechoiceforclinicalresearchapplications.However,lowerexpansionratesinfeeder-

freeculturesystemspresentachallengetowidespread

adoption.Thisisakeyreasonwhyfeeder-basedexpansionsystemsarestillfrequentlyuseddespitethesafetyand

regulatoryriskstheypose.

Herewedescribetheexpansionandcharacterization

ofNKcellsgrowninafeeder-freeculturesystemusing

Gibco?CTS?NK-Xpander?Medium,whichcansupportanaverage1,500-foldexpansionofNKcellswithintwoweeks.

ThermoFisher

SCIENTIFIC

Materialsandmethods

EnrichedNKcellswereexpandedfor14daysineitherCTSNK-Xpander

Mediumwithsupplementation,classicmediumwithsupplementation,oranalternatefeeder-freemediasystem.

NKcellcultureswerefedevery

2–3daysbeginningonday5.Thelevelofexpansionwasmeasuredoneveryfeedday,andphenotypicandfunctionalcharacterizationwasperformedonday14(Figure2).

Feeder-freeNKcellexpansionCD56?NKcellsenriched

from20differentdonorsof

peripheralbloodmononuclearcells(PBMCs)wereplatedat

1.25x10?cells/mLin200μLperwellinuntreatedThermoScientific?Nunc?96-wellplates(Cat.No.268200).

Thecellswereculturedfor14days

inoneoffourmedia:(1)CTSNK-

XpanderMedium(Cat.No.A5019001)containing500U/mLrecombinant

humanIL-2(Cat.No.PHC0023)and5%hABserum(FisherScientific

Cat.No.BP2525100);(2)axeno-freeNKspecialtymediumfromsupplier1supplementedwith500U/mL

recombinanthumanIL-2and5%hABserumperproductinstructions;

(3)Gibco?RPMI1640Medium

(Cat.No.11875093)supplementedwith500U/mLrecombinant

humanIL-2and5%FBS(Cat.No.

16140063);and(4)RPMI1640

Mediumsupplementedwith500U/mLrecombinanthumanIL-2and5%

hABserum.Thecellswerestainedwithtrypanblue(Cat.No.15250061)

andcountedusingtheInvitrogen?Countess?2FLAutomatedCell

Counter(Cat.No.AMQAX1000).

Beginningonday5,cultureswerefedevery2–3daystomaintainanoptimalcelldensityof4–5x10?cells/mL.

25,000cellsplatedin96-wellplate

EnrichedNKcellsCD56+NKcells

fromPBMCs

CTSNK-XpanderMedium+5%hABserum

+500U/mLIL-2

14daysculturefeedingandsplittingevery2–3days

?Totalnucleatedcells

?Percentviability

?Flowphenotyping

?Cytotoxicityassessment

Figure2.PrimaryNKcellexpansionandcharacterizationmethodology.

NKcellphenotypiccharacterization

NKcellshavetraditionallybeenidentifiedbythepresenceofCD56andthe

absenceofCD3receptorsontheirsurfacesviaflowcytometry.NKcellscanbefurthercategorizedintoavarietyofsubsetsbasedonmanydifferentcellsurfacemarkers,includingCD16andtheKIRfamilyofreceptors.Fortheseexperiments,expandedNKcellsweregatedforlivecellsusingtheInvitrogen?LIVE/DEAD?

FixableDeadCellStainKit(Cat.No.L34964).ThelevelsofCD56,CD3,andCD16weremeasuredusinglabeledantibodiesspecifictothesemarkers,andtheInvitrogen?Attune?NxTAcousticFocusingCytometer(Cat.No.A42858).

NKcellfunctionality

Figure3illustratesthefunctionalcharacterizationstrategy.NKcells(effector

cells)expandedinCTSNK-XpanderMediumwereco-incubatedwithK562

targetcellslabeledwiththeInvitrogen?CellTrace?CFSECellProliferationKit

(Cat.No.C34570)for2hours.TheratiosofNKcellstoK562cellswere0.625:1,1.25:1,2.5:1,and5:1.Followingincubation,degranulationwasassessedbytheexpressionofCD107aonCD56?NKcells,measuredusingalabeledantibodyspecifictothismarker,andtheAttuneNxTAcousticFocusingCytometer.NK

cellcytotoxicitywasassessedbymeasuringK562celldeathontheAttune

NxTFlowCytometer;thegatewassetforCFSE-labeledK562cells,and

percentagesofliveanddeadcellsweredeterminedusingtheLIVE/DEADstainkit(Cat.No.L34964).

ExpandedNKcells

CSFE-labeledK562cells

+

Target

IncubateexpandedNKcellswithlabeledK562cellsfor2hr

?NKcelldegranulation

?MeasureK562celldeath

Efector

Figure3.NKcellfunctionalitywasassessedbymeasurementofdegranulationandtheabilityoftheNKcellstokillK562targetcells.

Results

NKcellsthatwereexpandedusingCTSNK-XpanderMediummaintainedtheirphenotypeandfunctionality.

Feeder-freeNKcellexpansion

PBMC-derivedNKcellsfrom20differentdonorswere

expandedfor14daysineitherCTSNK-XpanderMedium,classicmedia,oranNKspecialtymediumfromsupplier1.Asexpected,expansionlevelsvariedfromdonor

todonorandbetweenthedifferentmediasystems

tested.Cellexpansioninthedifferentmediaover14daysiscomparedinFigure4A,andFigure4Bshowsadonor-to-donorcomparison.ExpansioninCTSNK-Xpander

Mediumwassignificantlyhigherthanitwasinanyothermediumsystemtested(p<0.0001).InCTSNK-XpanderMedium,expansionwassignificantlyhigherthanitwasinthemediumfromsupplier1for80%ofthedonorstested.

Expansionofcellsfromthe20donorsinsupplier1mediumwas732-foldonaverageafter14days,whereasexpansionofcellsfromthesamedonorsinCTSNK-XpanderMediumwas1,508-foldonaverageafter14days.

A

Foldexpansion

1,800

1,600

1,400

1,200

1,000

800

600

400

200

0

Day5Day7Day10Day12Day14

Medium

NK-XpanderRPMI-FBS RPMI-hABSupplier1

B

Medium

NK-XpanderSupplier1

3,500

Day14foldexpansion

3,000

2,500

2,000

1,500

1,000

500

0

Donor1

Donor2

Donor3

Donor4

Donor5

Donor6

Donor7

Donor8

Donor9

Donor10

Donor11

Donor12

Donor13

Donor14

Donor15

Donor16

Donor17

Donor18

Donor19

Donor20

Donorblinded

Figure4.ExpansionofNKcellcultureinCTSNK-XpanderMediumcomparedtoexpansioninothermediasystems.(A)Average

expansionofcellsfrom20differentdonorsover14days.Errorbars

represent1standarderrorfromthemean.(B)Donor-to-donorcomparisonafter14daysofexpansion.Errorbarsrepresent1standarddeviationfromthemean.

NKcellphenotypiccharacterization

ThepurityofNKcellsexpandedinCTSNK-Xpander

Mediumandthesupplier1mediumwascomparable,whileNKcellsexpandedinRPMImediumsupplementedwith

eitherFBSorhABserumhadlowerpurity(Figure5).CellsgrowninCTSNK-XpanderMediumhadsignificantlygreaterexpansionbutsimilarpurityrelativetocellsgrowninotherNKcell–specificexpansionsystems.

A

B

Day14cellpurity

CelltypemNKcellsmNKTcellsTcells

100

%Celltype

80

Other

60

40

20

0

NK-XpanderRPMI-FBSRPMI-hABSupplier1

Medium

C

Foldexpansion

1,800

1,600

1,400

1,200

1,000

800

600

400

200

0

NK-XpanderRPMI-FBSRPMI-hABSupplier1

Medium

Figure5.PhenotypiccharacterizationofNKcells.ExpansionofNKcellsinCTSNK-XpanderMediumwassignificantlyhigher,withnoloss

inpurity.(A)Gatingstrategy,(B)purity,and(C)expansionbyday14indifferentmediasystems.Errorbarsrepresent1standarderrorfromthemean.

NKcellfunctionalityAB

NKcellsgrowninCTSNK-XpanderMediumretainedtheirdose-dependentabilitytodegranulate(Figure6),andtheydisplayedcytolyticfunctionality(Figure7)afterexposuretoK562targetcells.ThesearekeyindicatorsofNKcell

functionalityinvitro.

AB

Degranulation(%)

C

80

70

60

50

40

30

20

10

0

0.625:11.25:12.5:15:1

Cellkilling(%)

120

100

80

60

40

20

0

C

0.625:11.25:12.5:15:1

NK:K562ratio

Figure7.NKcellsexpandedinCTSNK-XpanderMediumcankill

K562targetcellsinadose-dependentmanner.Representativegating

isshownfor(A)K562cellsonlyand(B)K562cellsexposedtoNKcells.

(C)ThepercentageofK562cellkillingatvaryingratiosofNKcellstoK562cells.EachdotrepresentsoneNKcelldonor.

NK:K562ratio

Figure6.NKcellsexpandedinCTSNK-XpanderMediumarecapableofdegranulationinadose-dependentmanner,asdemonstrated

bysurfaceCD107aexpression.ComparisonofCD107aexpression

in(A)NKcellsonlyand(B)NKcellsexposedtoK562cells.(C)The

percentageofNKcelldegranulation(CD107a?)atvaryingratiosofNKcellstoK562cells.EachdotrepresentsoneNKcelldonor.

gibco

Conclusions

Whilefeeder-freeculturesystemsaretypicallyseenas

asaferchoiceforNKcellexpansionthanfeeder-basedculturesystems,NKcellexpansioninexistingfeeder-freesystemslikeRPMIandserumissignificantlylower.TherecentdevelopmentofNKcell–specificspecialtymediahasbegunthetransitiontotrulyfeeder-freeculture

systems,buttheystillleavemuchtobedesiredintermsofexpansion.

CTSNK-XpanderMediumoffersasolutiontothis

challenge:feeder-freeNKcellculturewithCTSNK-XpanderMediumcandeliveruptoanaverage1,500-foldexpansionoffunctionalNKcells.CTSNK-XpanderMediumisaxeno-freeNKcellculturemediumformulatedforfeeder-free

culturethatcanhelpreduceregulatoryrisksforyourNKcellexpansionprotocol.

Orderinginformation

Product

Quantity

Cat.No.

Expand

CTSNK-XpanderMedium

500mLbottle

A5019001

5Lbag

A5019002

HumanIL-2RecombinantProtein

1mg

PHC0023

CTSDPBS,withoutcalciumchloride,withoutmagnesiumchloride

2Lbag

A1285602

HumanABSerum

100mL

FisherScientific,BP2525100

Nuncnon-treated96-wellplates

Caseof160

268200

Nuncnon-treated48-wellplates

Analyze

Caseof75

150787

Countess3FLAutomatedCellCounter

1instrument

AMQAF2000

TrypanBlueSolution,0.4%

100mL

15250061

CellTraceCFSECellProlife

溫馨提示

  • 1. 本站所有資源如無特殊說明,都需要本地電腦安裝OFFICE2007和PDF閱讀器。圖紙軟件為CAD,CAXA,PROE,UG,SolidWorks等.壓縮文件請下載最新的WinRAR軟件解壓。
  • 2. 本站的文檔不包含任何第三方提供的附件圖紙等,如果需要附件,請聯(lián)系上傳者。文件的所有權(quán)益歸上傳用戶所有。
  • 3. 本站RAR壓縮包中若帶圖紙,網(wǎng)頁內(nèi)容里面會有圖紙預(yù)覽,若沒有圖紙預(yù)覽就沒有圖紙。
  • 4. 未經(jīng)權(quán)益所有人同意不得將文件中的內(nèi)容挪作商業(yè)或盈利用途。
  • 5. 人人文庫網(wǎng)僅提供信息存儲空間,僅對用戶上傳內(nèi)容的表現(xiàn)方式做保護處理,對用戶上傳分享的文檔內(nèi)容本身不做任何修改或編輯,并不能對任何下載內(nèi)容負責。
  • 6. 下載文件中如有侵權(quán)或不適當內(nèi)容,請與我們聯(lián)系,我們立即糾正。
  • 7. 本站不保證下載資源的準確性、安全性和完整性, 同時也不承擔用戶因使用這些下載資源對自己和他人造成任何形式的傷害或損失。

評論

0/150

提交評論